We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against the other ...

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Learn more about whether Alvotech or Blueprint Medicines Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Blueprint Medicines has a twelve month low of $73.04 and a twelve month high of $121.90. The stock’s 50 day moving average is $88.95 and its 200-day moving average is $93.26.

In the current U.S. market landscape, significant volatility has been observed as major indices like the Dow Jones and Nasdaq Composite experience sharp declines due to ongoing tariff concerns and ...

Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Stock analysts at Wedbush lowered their Q1 2025 earnings estimates for Blueprint Medicines in a research report issued on Wednesday ...

Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects ...

Wedbush analyst David Nierengarten maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...

Throughout the last three months, 14 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24 th ...

Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...